Prostate Cancer | Specialty

Dr. Shore Reviews Emerging Therapies in Prostate Cancer

December 12th 2012

Emerging Therapies in Prostate Cancer

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part II

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part I

December 12th 2012

NCCN Guidelines for Advanced Prostate Cancer

December 12th 2012

Immunotherapy in Advanced Prostate Cancer, Part II

December 12th 2012

Immunotherapy in Advanced Prostate Cancer, Part I

December 12th 2012

Managing ADT-Associated Skeletal-Related Events

December 12th 2012

Prostate Cancer Management: Introduction and Overview

December 12th 2012

FDA Approves Earlier Use of Abiraterone Acetate

December 10th 2012

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

Researchers Seek Optimal Dose of Cabozantinib in mCRPC

December 5th 2012

Single-agent cabozantinib has shown promising activity in early-stage trials involving heavily pretreated patients with metastatic castration-resistant prostate cancer. Researchers are now attempting to find the optimal dose of the drug in this patient population.

Dr. Taplin on the Mechanism of Action of Enzalutamide

November 29th 2012

Mary-Ellen Taplin, MD, from the Dana-Farber Cancer Institute, discusses unique mechanism of action of enzalutamide in metastatic castration-resistant prostate cancer.

Enzalutamide Delays First Skeletal-Related Event, Improves Pain and QOL in Patients With Metastatic Prostate Cancer

November 27th 2012

Enzalutamide significantly delayed the time to first SRE and significantly improved pain and QOL compared with placebo in men with mCRPC who had received prior docetaxel.

Team Finds 12 Markers for Radiation-Associated Erectile Dysfunction

November 16th 2012

A research team has discovered 12 genetic markers associated with the development of erectile dysfunction in prostate cancer patients treated with radiation.

In Prostate Cancer, Focus on AR Signaling Sharpens

November 13th 2012

A deeper understanding of androgen receptor signaling in castration-resistant prostate cancer has created an opportunity to deliver more effective therapies earlier in the treatment timeline.

Dr. Oh on Sequencing New Treatments for Prostate Cancer

November 12th 2012

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

Beta-Carotene Antioxidant Use Is Safe During Radiotherapy for Prostate Cancer

November 6th 2012

Men who take the dietary antioxidant beta-carotene while they are undergoing radiation therapy for prostate cancer do not have an increased risk of prostate cancer death or metastases.

Dr. Rotkowitz Describes Challenges Facing Immunotherapy

November 2nd 2012

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

Dr. Freedland on Treating Early-Stage Prostate Cancer

October 31st 2012

Stephen J. Freedland, MD, from Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.

Elevated Cholesterol Linked to Aggressive Prostate Cancer

October 29th 2012

Men with increased cholesterol levels may have an elevated risk of developing high-grade prostate cancer.